Janssen Biotech, Inc. v. Amgen Inc.
1:22-cv-01549
Overview
Parties
Defendant
Amgen Inc. Operating Company
Represented By
10 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Plaintiff
Janssen Biotech, Inc. Operating Company
Represented By
4 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 25 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 6,902,734 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 17,153,336 | European Counterpart (EP) | View Official Patent → |
| π¨π¦ Canada | CA 002418961 A | Canada Counterpart | View Official Patent → |
| π¨π¦ Canada | CA 2418961 C | Canada Counterpart | View Official Patent → |
| π¨π³ China | CN 2008101000 | China Counterpart | View Official Patent → |
| π¨π³ China | CN 101550190 B | China Counterpart | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 9,006,396 | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 10,184,116 | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 2,305,817 B1 | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 19,179,253 | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 3,597,752 A1 | European Counterpart (EP) | View Official Patent → |
| π©πͺ Germany | DE 1220090000 | Germany Counterpart | View Official Patent → |
| π―π΅ Japan | JP 2002517788 A | Japan Counterpart | View Official Patent → |
| π―π΅ Japan | JP 4731094 B2 | Japan Counterpart | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 1,959,598 A | European Counterpart (EP) | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6902734
Anti-IL-12 antibodies and compositions thereof
|
Filed: 2001-08-01
Issued: 2005-06-07
|
Expired (Term Ended)
+785d PTA
Expires: 2023-09-25
|
|
|
US10961307
Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody
|
Filed: 2019-09-24
Issued: 2021-03-30
|
Active (12.8 yrs remaining)
Expires: 2039-09-24
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
High PTA (+785 days) / Cellect Scrutiny β Over 785 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
12
Dispositive
2
Granted
0
Denied
0
Pending / Review
11
Motions by Category
Key Dispositive Motions & Rulings